Počet záznamov: 1
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial
SYS 0148616 LBL 00000naa--2200000-a-4500 005 20250607164756.6 008 180815s2018----xo-----e------------eng-- 040 $a BA006 $b slo 041 0-
$a eng 044 $a xo $c SK 245 10
$a Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial / $c Sufliarsky J. ... [et al.] 500 $a The Lancet resporatory medicine, vol. 6, no. 6 (2018), s. 431-441 650 12
$7 sllk_us_auth*d012509 $a sarkóm $x farmakoterapia $2 mesh 650 12
$7 sllk_us_auth*d000077548 $a kináza anaplastického lymfómu $x antagonisty a inhibítory $2 mesh 650 12
$7 sllk_us_auth*d017322 $a skúšanie klinické, fáza II, ako téma $2 mesh 650 22
$7 sllk_us_auth*d016896 $a výsledok liečby $2 mesh 650 22
$7 sllk_us_auth*d064420 $a účinky liekov vedľajšie a nežiaduce reakcie liekov $2 mesh 653 2-
$a krizotinib 653 2-
$a nádory inflamatórne myofibroblastické 700 1-
$7 sllk_us_auth*p0050766 $a Šufliarsky, Jozef $u II. onkologická klinika LF UK a NOÚ, Bratislava $4 ant 710 2-
$7 sllk_us_auth*0012742 $a Redakcia Onkológia $4 adp 773 0-
$7 nnas $w sllk_us_cat*0147827 $t Onkológia $x 1336-8176 $d Bratislava : SOLEN, 2018 $g Roč. 13, č. 3 (2018), s. 222-223
Počet záznamov: 1